Astra Zeneca AB
AstraZeneca is a leading biopharmaceutical company delivering great medicines to patients through innovative science and excellence in development and commercialisation.
Research and Development of AstraZeneca is conducted in six countries, of these focus will be on three strategic research centers in Sweden (Mölndal), United Kingdom and USA. Supply and Manufacturing sites are located in 16 countries. AstraZeneca operates in over 100 countries and has approximately 51,700 employees.
At AstraZeneca Mölndal, research is focused in two Innovative Medicines Units - Cardiovascular & Metabolic Diseases iMED and Respiratory, Inflammation and Autoimmunity iMED. There is also a large development organization, primarily made up of Clinical, Pharmaceutical Development and Regulatory Affairs.
The Mölndal site also houses the global center for producing transgenic animals to create models of human diseases, and an additional center of excellence in the area of inhalation technologies is currently under construction.
In total 2 400 employees work at AstraZeneca Mölndal, the vast majority within research and development. Our scientists work in close collaboration with numerous academic institutions and partners around the globe, giving us access to a worldwide network of expertise and innovation.
Research in Mölndal has resulted in several important medicines, including the anti-hypertensive Seloken®/Toprol XL/Betaloc® (metoprolol), the proton pump inhibitors Losec® (omeprazole) and Nexium® (esomeprazole) for the treatment of peptic ulcer and acid reflux related diseases, and from Lund, Symbicort® (budesonide/formoterol) for managing patients with asthma and COPD.